ArticleNature medicine2018
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
Erratum issued 2 registry-linked trialsOpen access · greenAbstract read
In one paragraph
Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 1,144 papers.
0numbers the graph read from it
0cells of the map it votes in
1,144citing papers in PubMed
60.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor-modified Autologous T Cells (CART19) in Patients with Relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma. a Dose Escalation, Open-label, Phase I Study.
NCT05199311 phase1 / phase2suspendednot on this mapstarted 2022, after this paper: background citation
A Phase I/II Study of Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Patients With Newly Diagnosed Transplant Eligible Multiple Myeloma
Who cites it
1,144 citing papers in PubMed, 1,698 citations in OpenAlex.
- A distinct CAR-T cell phenotype mediates therapeutic response at limited doses.Nature communications · 2026Trial
- Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial.Nature communications · 2026Trial
- Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomas.Blood neoplasia · 2026Trial
- Remodeling memory T cells with chemotherapy and immune checkpoint inhibitors as host pre-conditioning to empower in vivo CAR-T therapy.Synthetic and systems biotechnology · 2026Review
- Research trends and hotspots of CAR-T cell therapy for acute lymphoblastic leukemia: A bibliometric analysis.Human vaccines & immunotherapeutics · 2026Article
- CAR-T-centered sequential therapy: current status, challenges, and future clinical perspectives.Journal of hematology & oncology · 2026Review
- Clonal Hematopoiesis and CAR T Cell Therapy: From Biological Crosstalk to Clinical Implications.International journal of laboratory hematology · 2026Review
- CAR-T TEMRA and CAR-Tregs in vivo expansion are both associated with a poor response after CD19.CAR-T therapy.Bone marrow transplantation · 2026Article
- Advancing In Vivo Chimeric Antigen Receptor T-Cell Engineering to Accelerate Clinical Translation.MedComm · 2026Review
- Antibody-lectin chimeras for glyco-immune checkpoint blockade.Nature biotechnology · 2026Article
- Drugging the immune system: principles of immunopharmacology.Nature reviews. Immunology · 2026Article
- FOXP1 Knockdown Reprograms Th9 CAR-T Cells to Overcome Antigen Escape.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Generation of Allogeneic CAR-T Circumvents Functional Deficits in Patient-Derived Autologous Product for Glioblastoma.International journal of cancer · 2026Article
- Review
- Boosting T cell antioxidant capacity: A strategic approach to overcome immunosuppression in solid tumors.Redox biology · 2026Review
- CRISPRing through time: How cutting-edge technology is revolutionizing life sciences and medicine.Molecular therapy. Nucleic acids · 2026Review
- Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion.Nature communications · 2026Article
- Recent advances in molecular mechanisms to improve the efficacy of CAR-T cell therapy for viral diseases, cancer, and autoimmune diseases.Stem cell research & therapy · 2026Review
- Microfluidic-based rapid generation of chimeric antigen receptor T cells improves low-multiplicity-of-infection transduction efficiency while preserving functional activity.Journal of translational medicine · 2026Article
- Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies.Experimental hematology & oncology · 2026Review
1,084 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
37 authors at 3 institutions in 1 country.
Joseph A FraiettaDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Simon F Lacey *Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Elena J Orlando *Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
Iulian Pruteanu-MaliniciNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
Mercy GohilCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Stefan LundhCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Alina C BoesteanuCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Yan WangCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Roddy S O'ConnorCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Wei-Ting HwangDepartment of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA.
Edward PequignotCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
David E AmbroseCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Changfeng ZhangCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Nicholas WilcoxCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Felipe BedoyaCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Corin DorfmeierCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Fang ChenCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Lifeng TianCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Harit ParakandiCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Minnal GuptaCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Regina M YoungCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
F Brad JohnsonDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-7443-7227
Irina KulikovskayaCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Li LiuCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Jun XuCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-6969-0693
Sadik H KassimNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
Megan M DavisDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Bruce L LevineDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-6971-8465
Noelle V FreyCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Donald L SiegelDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Alexander C HuangParker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA.
E John WherryParker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA.
Hans BitterNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
Jennifer L BrogdonNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
David L PorterDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Carl H JuneDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-0241-3557
J Joseph MelenhorstDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@upenn.edu.
University of Pennsylvania · USParker Institute for Cancer Immunotherapy · USNovartis (United States) · US
Funding
UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SHELLEY L BERGER · 1985 to 2026
$222.3MProject 3: Combinatorial and gene-editing approaches to enhance the efficacy of CAR T cell therapy of multiple myeloma.P01CA214278 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CARL H. JUNE · 2017 to 2026
$26.8MIMMUNOBIOLOGY OF NORMAL AND NEOPLASTIC LYMPHOCYTEST32CA009140 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Malay Haldar, WARREN S PEAR · 1985 to 2026
$16.1MCD19 Directed CAR TherapyR01CA165206 · NCI · UNIVERSITY OF PENNSYLVANIA · PI JUNE, CARL H., PORTER, DAVID L · 2012 to 2016
$2.2MNCI NIH HHS P01 CA214278NCI NIH HHS P30 CA016520NCI NIH HHS R01 CA165206NCI NIH HHS T32 CA009140
Abstract
Tolerance to self-antigens prevents the elimination of cancer by the immune system
Indexed as
Immunotherapy, AdoptiveAnimalsAntigens, CD19FemaleInterleukin-6Leukemia, Lymphocytic, Chronic, B-CellMaleMiceReceptors, Chimeric AntigenSTAT3 Transcription FactorTranscription, GeneticTreatment OutcomeAntigens, CD19Interleukin-6Receptors, Chimeric AntigenSTAT3 Transcription Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05054257ClinicalTrials.gov
NCT05199311ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.